Metabolic Outcomes and Recurrent Weight Gain 10 Years After Roux-en-Y Gastric Bypass, a Longitudinal Cohort Study

Figures

• 

  Fig. 1. Study inclusion of patients attending 10-year follow-up consultations after Roux-en-Y gastric bypass

• 

  Fig. 2. a Weight (kg) at baseline and two, five and 10 years after Roux-en-Y gastric bypass in patients with and without significant recurrent weight gain (RWG) at 10-year follow-up consultations. b BMI (kg/m2) at baseline and two, five and 10 years after Roux-en-Y gastric bypass in patients with and without significant recurrent weight gain (RWG) at 10-year follow-up

• 

  Fig. 3. Obesity related diseases from baseline to follow-up 10-years after Roux-en-Y gastric bypass (N=311 patients). Statistically significant changes: Significant reduction in the prevalence of diabetes type 2, hypertension and dyslipidemia from baseline to 10-year follow-up (p<0.001, McNemar). Significant increase in diabetes from five to 10-year follow-up (0000<0.001, McNemar). Significant reduction in the prevalence of diabetes type 2, hypertension and dyslipidemia from baseline to two-year follow-up (p<0.001, McNemar). From two-year to five-year follow-up, significant increase in hypertension (p<0.001) and dyslipidemia (p=0.045, McNemar). From two-year to 10-year follow-up, significant increase in diabetes type 2 (p=0.002), hypertension (p=0.014) and dyslipidemia (p=0.005, McNemar)

• 

  Fig. 4. Status of diabetes type 2, hypertension and dyslipidemia from two to 10-year follow-up after Roux-en-Y gastric bypass in patients according to recurrent weight gain (RWG). Change between two-year and 10-year follow values calculated as 10-year values minus two-year values. “No change” is defined as patients with no dyslipidemia or unchanged status